eIF5B increases ASAP1 expression to promote HCC proliferation and invasion

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality globally.
• Despite advances, the molecular drivers of HCC progression remain incompletely understood.
• Identifying novel molecular targets and biomarkers is crucial for improving HCC patient outcomes.

Purpose of the Study:

• To investigate the role of eukaryotic translation initiation factor 5B (eIF5B) in HCC pathogenesis.
• To determine the correlation between eIF5B expression and clinical characteristics, including survival.
• To elucidate the molecular mechanisms by which eIF5B influences HCC progression.

Main Methods:

• Analysis of eIF5B expression in a large cohort of HCC patients.
• Correlation analysis between eIF5B levels and clinicopathological features, recurrence-free survival (RFS), and overall survival (OS).
• In vitro and in vivo experiments to assess the impact of eIF5B on HCC cell proliferation, migration, and ASAP1 expression.

Main Results:

• Elevated eIF5B expression was significantly associated with aggressive HCC characteristics.
• Higher eIF5B levels correlated with shorter RFS and OS in HCC patients.
• eIF5B overexpression promoted HCC cell proliferation and migration.
• eIF5B-induced HCC progression was partly mediated by increased ASAP1 expression.

Conclusions:

• eIF5B is upregulated in HCC and promotes tumor progression.
• eIF5B serves as a potential prognostic biomarker for HCC.
• Targeting eIF5B may offer a therapeutic strategy for improving HCC outcomes.